Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 725 of 5804
-
Promising new combo tackles tough bone cancer
Disease control CompletedThis study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Phase: PHASE1, PHASE2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can zapping a few spots keep lung cancer in check?
Disease control OngoingA registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy…
Phase: PHASE2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a simple shot help fight tough leukemia?
Disease control OngoingThe Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to determine the maximum tolerated dose (MTD), and recommende…
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for bladder cancer patients who can't have standard chemo
Disease control CompletedThis is a pre-surgical study involving subjects with muscle invasive bladder urothelial cancer, who are candidates for cisplatin ineligible neoadjuvant therapy. It is a one-arm phase II study in single center.
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
ER-based program aims to stop opioid addiction before it starts in young people
Prevention CompletedThe purpose of the study is to develop and test innovative interventions to prevent the development of opioid misuse and opioid use disorders among older adolescents and young adults (AYA; ages 16-30) who use opioids, which will be initiated from a health care visit in the emerge…
Phase: NA • Sponsor: University of Michigan • Aim: Prevention
Last updated Jun 27, 2026 09:00 UTC
-
Can a second treatment boost motor skills in SMA kids after gene therapy?
Disease control CompletedIn this study, researchers will learn more about the use of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study will focus on children under the age of 3 who were previously treated with the gene therapy onasemnogene abeparvovec but are still facin…
Phase: PHASE4 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Rectal cancer breakthrough: immunotherapy may replace surgery for some
Disease control Recruiting nowImmunotherapy has achieved significant therapeutic effect in DNA mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC) , more than fifty percent of dMMR/MSI-H CRC patients might get pathological complete response(pCR) after PD-1 monoclo…
Phase: NA • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for kids with kidney disease: rituximab cuts relapse risk
Disease control CompletedThis study investigated the combined impact of rituximab and targeted nursing care versus tacrolimus and targeted nursing care on efficacy, quality of life, adverse reactions, and recurrence rate in children with challenging (steroid-dependent or frequently relapsing) nephrotic s…
Phase: NA • Sponsor: Wuhan Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Which ablation works best for AFib with heart failure? new trial aims to find out
Disease control OngoingAtrial fibrillation (AF) in the context of heart failure (HF) is associated with a markedly poor prognosis. Catheter ablation has been shown to improve outcomes in this population, enhancing ablation success rates in these patients is critical for further reducing morbidity and m…
Phase: NA • Sponsor: Xu Liu • Aim: Disease control
Last updated Jun 26, 2026 13:54 UTC
-
Gene test could revolutionize prostate cancer screening
Diagnosis OngoingAt the present moment, there is no international consensus on the optimal screening to perform in men with a specific genetic/molecular risk for PCa. The number of studies exploring screening strategies tailored to men with a family history for PCa is limited \[15-17\]: most of t…
Sponsor: Istituto Clinico Humanitas • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
Triple therapy boosts survival in tough liver cancer cases
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with high tumor burden advanced-stage hepatocellular carcinoma (HCC) with portal vein tumor thrombus (P…
Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Heart attack survivors: new drug may cut risk of another cardiac event
Disease control CompletedThe goal of this Target Trial Emulation (TTE) study is to evaluate the effect of evolocumab on clinical prognosis in patients with multivessel disease (MVD) following acute myocardial infarction (AMI) who have deferred non-culprit vessel. The main question it aims to answer is: …
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Stitch vs plug: new heart hole closure device tested to stop strokes
Disease control Recruiting nowSTITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch™ EL versus FDA-approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent Ischemic stroke.
Phase: NA • Sponsor: Nobles Medical Technologies II Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a pill combo keep melanoma from coming back?
Disease control OngoingThis is a prospective, open label, single-arm, multicenter, non-interventional study of dabrafenib in combination with trametinib as adjuvant treatment for Chinese patients with stage III BRAF V600 mutation positive melanoma after complete resection.
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug A140 challenges standard treatment for colorectal cancer
Disease control CompletedCompare the objective remission rate of A140 and Erbitux combined with mfolfox6 regimen in the first-line treatment of Ras wild-type metastatic colorectal cancer for 12 weeks
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy aims to keep high-risk neuroblastoma from coming back
Disease control OngoingThis phase II trial studies if dinutuximab, GM-CSF, isotretinoin in combination with irinotecan, and temozolomide (chemo-immunotherapy) can be given safely to patients with high-risk neuroblastoma after Consolidation therapy (which usually consists of two autologous stem cell tra…
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
DNA vaccine against COVID-19 shows promise in early trial
⭐️ VACCINE ⭐️ CompletedThis clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) in healthy volunteers.
Phase: PHASE1, PHASE2 • Sponsor: GeneOne Life Science, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 12:56 UTC
-
Immunotherapy cocktail aims to boost breast cancer remission before surgery
Disease control OngoingThis is a Phase II, randomized, open-label trial to evaluate the clinical and immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple negative breast cancer (TNBC).
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental combo shows promise for Hard-to-Treat melanoma
Disease control CompletedThis is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma that h…
Phase: PHASE2 • Sponsor: Highlight Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug cocktail targets tough blood cancers
Disease control Recruiting nowThis phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has IDH1 mutation. The safety of this drug combination will also be studied. IDH1 is a type of genetic mutation (chang…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC